Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2017.357 | A Phase Ib/II, open label, multicenter study of MCS110 in combination with PDR001 in patients with advanced malignancies |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2015.389 | A Phase Ib/II, Multicentre, Open Label, Randomised Study of BI 836845 in Combination with Enzalutamide, versus Enzalutamide alone, in Metastatic Castration-Resistant Prostate Cancer (CRPC) Following Disease Progression on Docetaxel-Based Chemotherapy and Abiraterone |
Dr. HO Wing Ming 何永明醫生 |
| 2019.652 | A phase Ib/II, multicenter open-label study of CS1001 in combination with regorafenib in patients with advanced or refractory solid tumors | Dr. LOONG Herbert Ho Fung |
| 2020.626 | A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2019.327 | A Phase Ib, open-label, multi-center study to characterize the safety, tolerability, and preliminary efficacy of TNO155 in combination with spartalizumab or ribociclib in selected malignancies |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2017.452 | A Phase Ib, Open Label, Multiple Ascending Dose, Pilot Study to Assess the Safety, Preliminary Efficacy and Pharmacokinetics of Subcutaneously Administered APL-2 in Subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH). – PADDOCK – |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2018.553 | A phase Ib, open label, multi-center study to characterize the safety, tolerability and preliminary efficacy of EGF816 in combination with selected targeted agents in EGFR mutant NSCLC |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2018.436 | A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select immunotherapy combinations in adult patients with triple negative breast cancer |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2013.392 | A phase Ib trial of LEE011 in combination with everolimus (RAD001) and exemestane in the treatment of postmenopausal women with hormone receptor positive HER2 negative locally advanced or metastatic breast cancer | Prof. MA Brigette Buig Yue |
| 2014.357 | A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) ADMINISTERED WITH ERLOTINIB OR ALECTINIB IN PATIENTS WITH ADVANCED NON−SMALL CELL LUNG CANCER | Prof. MA Brigette Buig Yue |
| 2017.049 | A phase Ib study of PDR001 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2014.662 | A phase Ib dose-finding study of BYL719 plus everolimus and BYL719 plus everolimus plus exemestane in patients with advanced solid tumors, with dose-expansion cohorts in renal cell cancer (RCC), pancreatic neuroendocrine tumors (pNETs), and advanced breast cancer (BC) patients. | Prof. MA Brigette Buig Yue |
| 2012.315 | A phase Ib dose escalation/randomized phase II, multicenter, open-label study of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma | Prof. MA Brigette Buig Yue |
| 2019.555 | A Phase Ia/Ib, Open-Label, Dose-Escalation and Dose-Expansion Study of the Anti-CTLA-4 Monoclonal Antibody CS1002 as Monotherapy and in Combination with Anti-PD-1 Monoclonal Antibody CS1003 in Subjects with Advanced Solid Tumors |
Dr. CHAN Stephen Lam 陳林 |
| 2009.588 | A Phase I/Iia, Open-Label, Crossover, Dose-Escalation, and Multi-Center Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc in Previously Treated Patients with Severe Hemphilia A | Professor II Cheng Greory |
| 2016.625 | A Phase I/IIa Study of BMS 986148, a Mesothelin Directed Antibody Drug Conjugate, in Subjects with Select Advanced Solid Tumors |
Dr. LOONG Herbert 龍浩鋒 |
| 2009.186 | A Phase I/IIa Safety and Pharmacokinetic Study of Intravenous FIXFc Administration to Previously Treated Hemophilia B Patients | Prof. Cheng Gregory |
| 2009.275 | A Phase I/II, Open-label, Multicentre Study to Assess the Safety & Tolerability, and Pharmacokinetics of AZD8055 in Asian Patients with Advanced Stage Hepatocellular Carcinoma (HCC) and with Mild or Moderate Hepatic Impairment | Prof Brigette Ma |
| 2023.373 | A Phase I/II, Open-Label, Multi-Center Study of ALE.C04 (anti-Claudin-1 Antibody) as a Single Agent and in Combination with Pembrolizumab (anti-PD-1 antibody) in Adult Patients with Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma | Prof. MA Brigette Buig Yue |
| 2020.221 | A Phase I/II, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Pediatrics with Locally Advanced or Metastatic Solid or Primary CNS Tumors and/or Who Have no Satisfactory Treatment Options |
Dr KU Dennis Tak Loi 古德來 |
| 2015.442 | A Phase I/II, open label, multicenter study of the safety and efficacy of LAG525 single agent and in combination with PDR001 administered to patients with advanced malignancies |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2014.535 | A phase I/II, multicenter, open-label study of oral FGF401 in adult patients with hepatocellular carcinoma or solid malignancies characterized by positive FGFR4 and KLB expression | Prof. CHAN Stephen Lam |
| 2016.385 | A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2017.540 | A phase I/II study of safety and efficacy of ribociclib (LEE011) in combination with trametinib (TMT212) in patients with metastatic or advanced solid tumors |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2005.288 | A Phase I/II Study of PXD101 in Patients with Unresectable Hepatocellular Carcinoma With Pharmacokinetic and Pharmacodynamic Evaluation | Prof. Yeo Winnie |
| 2020.054 | A phase I/Ib, open-label, multi-center, study of KAZ954 as a single agent and in combination with Spartalizumab, NZV930 and NIR178 in patients with advanced solid tumors |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2019.002 | A phase I/Ib, open-label, multi-center, study of DKY709 as a single agent and in combination with PDR001 in patients with advanced solid tumors |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2019.153 | A Phase I/Ib, open-label, multi-center study of NZV930 as a single agent and in combination with PDR001 and/or NIR178 in patients with advanced malignancies |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2017.328 | A PHASE I, SPONSOR-OPEN, INVESTIGATOR-BLINDED, SUBJECT-BLINDED, MULTI-CENTER, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ORAL ADMINISTRATION OF RO7020531: (1). SINGLE AND MULTIPLE ASCENDING DOSES IN HEALTHY MALE AND FEMALE SUBJECTS; (2). 6-WEEK TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION |
Prof. CHAN Lik Yuen 陳力元 |
| 2009.328 | A Phase I, Randomised, multi-centre, open-label study to determine the pharmacokinetics and tolerability of cediranib (RECENTIN | Associate Professor Brigette Ma |
| 2022.262 | A phase I, open-label, multi-center study of KFA115 as a single agent and in combination with pembrolizumab in patients with select advanced cancers | Prof. MA Brigette |
| 2005.338 | A Phase I, Multi-Centre, Randomized, Placebo-Controlled, Dose Escalation Study to Assess the Local and Systemic Tolerability of the Therapeutic DNA Plasmid PDPSC18 Vaccine Administered by Particle Mediated Epidermal Delivery Using the Powderject ND10 Delivery System in Subjects with Chronic Hepatitis B Infection | Dr. Leung Wai Yee Nancy |
| 2005.341 | A Phase I, Multi-Centre, Randomized, Placebo-Controlled, Dose Escalation Study to Assess the Local and Systemic Tolerability of the Therapeutic DNA Plasmid pdpSC18 Vaccine Administered by Particle Mediated Epidermal Delivery Using the PowderJect ND10 Delivery System in Subjects with Chronic Hepatitis B Infection | Prof. Chan LY Henry |
| 2005.229 | A Phase I, Dose Escalation Trial of Recombinant Modified Vaccinia Ankara (MVA)-based Vaccine Encoding Epstein-Barr Virus Target Antigens | Prof. Chan T.C. Anthony |
| 2006.024 | A Phase I Trial of 5-Azacitidine and Suberoylanilide Hydroxamic Acid in Patients with Metastatic or Locally Recurrent Nasopharyngeal Carcinoma and Nasal NK-T Cell Lymphoma | Prof. CHAN Anthony T. C. |
| 2023.314 | A PHASE I STUDY TO INVESTIGATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7565020 IN HEALTHY PARTICIPANTS AND IN PARTICIPANTS WITH CHRONIC HEPATITIS B VIRUS INFECTION | Prof. LUK Andrea On Yan |
| 2023.273 | A PHASE I STUDY TO INVESTIGATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7565020 IN HEALTHY PARTICIPANTS AND IN PARTICIPANTS WITH CHRONIC HEPATITIS B VIRUS INFECTION |
Prof. WONG Grace Lai Hung 35053759 |
| 2002.331 | A Phase I Study of Selective Intra-arterial High-dose Cisplatin Infusion and Accelerated Fractionation Radiotherapy for Non-metastatic Stage III and IV Head and Neck Squamous Cell Carcinomas | Dr. Yu Kwok Hung |
| 2024.239 | A PHASE I STUDY OF ERY974 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA | Prof. CHAN Stephen Lam |
| 2006.090 | A Phase I Study of CCI-779 in Combination with Imatinib Mesylate in Chronic Myelogenous Leukemia | Dr. Lei IK Kenny |
| 2012.129 | A phase I open-label dose escalation study with expansion to assess the safety and tolerability of INC280 in patients with c-MET dependent advanced solid tumors | Prof. MA Brigette Buig Yue |
| 2009.222 | A phase I dose escalation, multi-center, open-label study of HSP990 administered orally in adult patients with advanced solid malignancies | Prof. Ma Brigette |
| 2002.443 | A Phase I Dose Escalation Study to Evaluate the Safety of T138067-sodium Administered Weekly in Patients with Advanced Refractory Cancer | Prof. Mok Tony |
| 2003.244 | A Phase I Clinical and Molecular Study of Ganciclovir in Combination with Cisplatin and 5-Fluorouracil Chemotherapy in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma | Prof. Hui P. Edwin |
| 2020.454 | A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH |
Prof. NG Chi Fai 吳志輝 |
| 2011.233 | A Phase 4, Randomized, Open-label, Active-Controlled, Superiority Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination with Peginterferon α-2a (Pegasys®) versus Standard of Care Tenofovir Disoproxil Fumarate Monotherapy or Peginterferon α-2a Monotherapy for 48 Weeks in Non-Cirrhotic Subjects with HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B (CHB) | Prof. CHAN Henry Lik Yuen |
| 2011.225 | A Phase 4, Randomized, Open-label, Active-Controlled, Superiority Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination with Peginterferon α-2a (Pegasys®) versus Standard of Care Tenofovir Disoproxil Fumarate Monotherapy or Peginterferon α-2a Monotherapy for 48 Weeks in Non-Cirrhotic Subjects with HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B (CHB) | Dr. Hui Aric Josun |
| 2014.681 | A Phase 4, Open-Label Study in patients from Asia with Gastroesophageal Reflux Disease Treated with Dexlansoprazole | Prof. WU Justin Che Yuen |
| 2021.568 | A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants with Active Psoriatic Arthritis Axial Disease |
Prof. TAM Lai Shan 譚麗珊 |
| 2017.422 | A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cholangitis |
Prof. WONG Vincent W.S. 黃偉燊 |
Page 234 of 254.